M. Curry

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

A. Ghose, P. Dobrzanski, E. Bruckheimer, 2016, Journal of medicinal chemistry.

Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.

E. D. De Souza, F. Hobbs, A. Cocuzza, 1999, Journal of medicinal chemistry.

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

A. Ghose, B. Ruggeri, K. Wells-Knecht, 2012, Journal of medicinal chemistry.

A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Jennifer L. Mason, Pawel Dobrzanski, Bruce D. Dorsey, 2012, Journal of medicinal chemistry.

Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.

G. Trainor, L. Fitzgerald, R. Zaczek, 1999, Bioorganic & medicinal chemistry letters.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

C. Hodge, Y. Wong, F. Hobbs, 1999, Journal of medicinal chemistry.

4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors.

D. Kitchen, Shuang Liu, R. Olson, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.

Andrew V. Anzalone, B. Ruggeri, T. Underiner, 2010, ACS medicinal chemistry letters.